文献速递血栓与止血

COVID-19疫苗接种后静脉血栓栓塞症的风险

Risk of venous thromboembolism after COVID-19 vaccination.
PubMed 文献 · J Thromb Haemost · 2022-04-20

该研究基于Mayo Clinic电子病历,比较2020年11月1日至2021年11月1日期间≥18岁COVID-19疫苗接种者接种后90天与接种前90天的急性VTE发生率。共纳入792 010例接种者,接种后VTE风险与接种前相比无显著升高,Janssen、Moderna和Pfizer疫苗的aHR分别为0.97、1.02和1.00。

要点

  • 在792 010例COVID-19疫苗接种者中,接种后90天VTE风险与接种前90天相比无显著增加。
  • Janssen疫苗aHR 0.97(95%CI 0.63-1.50),Moderna疫苗aHR 1.02(95%CI 0.87-1.19),Pfizer疫苗aHR 1.00(95%CI 0.87-1.15)。
  • 接种后VTE发生率:Moderna 0.11%(IR 4.58/1000人年),Pfizer 0.09%(IR 3.84/1000人年),Janssen 0.09%(IR 3.56/1000人年)。

核心结论

  • 在这大型COVID-19疫苗接种队列中,未发现美国授权疫苗增加接种后急性VTE风险。

研究设计与样本

  • 研究比较COVID-19疫苗接种前后VTE发生率,利用Mayo Clinic enterprise电子病历分析2020年11月1日至2021年11月1日期间≥18岁疫苗接种者。

主要发现

  • 共识别792 010例至少接种一剂COVID-19疫苗的患者(Pfizer 452 950例,Moderna 290 607例,Janssen 48 453例)。
  • 接种前90天发生VTE事件772例,接种后90天发生793例,共1565例。
  • 接种后VTE:Moderna组326例(0.11%,IR 4.58/1000人年),Pfizer组425例(0.09%,IR 3.84/1000人年),Janssen组42例(0.09%,IR 3.56/1000人年)。
  • 与接种前时间段相比,Janssen疫苗aHR 0.97(95%CI 0.63-1.50),Moderna疫苗aHR 1.02(95%CI 0.87-1.19),Pfizer疫苗aHR 1.00(95%CI 0.87-1.15)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: COVID-19 vaccinations in the United States are effective in preventing illness and hospitalization yet concern over post-vaccination venous thromboembolism (VTE) risk has led to vaccine hesitancy. METHODS: The aim of this study was to compare VTE rates before and after COVID-19 vaccination. COVID-19 vaccinated patients ≥18 years between November 1, 2020 through November 1, 2021 were analyzed using electronic medical records across the Mayo Clinic enterprise. The primary outcome was imaging confirmed acute VTE (upper or lower deep vein thrombosis or pulmonary embolism) occurring 90 days before and after the date of first vaccine dose. RESULTS: A total of 792 010 patients with at least one COVID-19 vaccination were identified (Pfizer, n = 452 950, Moderna, n = 290 607, and Janssen [Johnson & Johnson], n = 48 453). A total of 1565 VTE events occurred in the 90 days before (n = 772) and after (n = 793) COVID-19 vaccination. VTE post-vaccination occurred in 326 patients receiving Moderna (0.11%, incidence rate [IR] 4.58 per 1000p-years), 425 patients receiving Pfizer (0.09%, IR 3.84 per 1000p-years), and 42 receiving Janssen (0.09%, IR 3.56 per 1000p-years). Compared to the pre-vaccination timeframe, the adjusted hazard ratio (aHR) for VTE after the Janssen vaccination was 0.97 (95% confidence interval [CI] 0.63-1.50), aHR 1.02 (95% CI 0.87-1.19) for Moderna, and aHR 1.00 (95% CI 0.87-1.15) for Pfizer. CONCLUSION: In this large cohort of COVID-19 vaccinated patients, no increased risk for acute VTE post-vaccination was identified for the authorized vaccines in the United States.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Houghton DE, Wysokinski W, Casanegra AI, et al. Risk of venous thromboembolism after COVID-19 vaccination. J Thromb Haemost. 2022. PMID: 35398975. doi:10.1111/jth.15725

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。